Enanta Pharmaceuticals (ENTA) Short Interest Ratio & Short Volume $10.71 +0.04 (+0.40%) As of 10:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Enanta Pharmaceuticals Short Interest DataEnanta Pharmaceuticals (ENTA) has a short interest of 3.35 million shares. This marks a 17.54% increase in short interest from the previous month. The short interest ratio (days to cover) is 5.7, indicating that it would take 5.7 days of the average trading volume of 403,738 shares to cover all short positions.Current Short Interest3,350,000 sharesPrevious Short Interest2,850,000 sharesChange Vs. Previous Month+17.54%Dollar Volume Sold Short$40.10 millionShort Interest Ratio5.7 Days to CoverLast Record DateSeptember 30, 2025Outstanding Shares21,380,000 sharesPercentage of Shares Shorted15.67%Today's Trading Volume44,234 sharesAverage Trading Volume403,738 sharesToday's Volume Vs. Average11% Short Selling Enanta Pharmaceuticals? Sign up to receive the latest short interest report for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartENTA Short Interest Over TimeENTA Days to Cover Over TimeENTA Percentage of Float Shorted Over Time Enanta Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 9/30/20253,350,000 shares $40.10 million +17.5%N/A5.7 $11.97 9/15/20252,850,000 shares $21.26 million +0.7%14.4%15.8 $7.46 8/31/20252,830,000 shares $23.77 million -1.7%14.3%16.3 $8.40 8/15/20252,880,000 shares $23.04 million +5.5%14.5%16.9 $8.00 7/31/20252,730,000 shares $20.69 million +11.0%13.8%17 $7.58 7/15/20252,460,000 shares $16.21 million +1.7%12.4%15.2 $6.59 6/30/20252,420,000 shares $18.30 million -3.2%12.2%13.3 $7.56 6/15/20252,500,000 shares $18.75 million -8.1%12.6%13.3 $7.50 5/31/20252,720,000 shares $16.24 million -4.6%13.7%13.9 $5.97 5/15/20252,850,000 shares $15.30 million -3.7%14.4%12.7 $5.37 Get the Latest News and Ratings for ENTA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 4/30/20252,960,000 shares $18.03 million +5.7%14.9%9.1 $6.09 4/15/20252,800,000 shares $14.42 million +4.9%14.1%8.1 $5.15 3/31/20252,670,000 shares $14.74 million +1.5%13.5%6.3 $5.52 3/15/20252,630,000 shares $17.49 million +1.2%13.3%5.2 $6.65 2/28/20252,600,000 shares $20.23 million -27.2%13.1%4.6 $7.78 2/15/20253,570,000 shares $25.49 million +6.3%18.0%6.2 $7.14 1/31/20253,360,000 shares $17.17 million +4.0%16.9%6.9 $5.11 1/15/20253,230,000 shares $15.57 million -3.6%16.4%7.3 $4.82 12/31/20243,350,000 shares $19.26 million -0.6%17.0%8.8 $5.75 12/15/20243,370,000 shares $20.32 million +4.3%17.1%12.2 $6.03 11/30/20243,230,000 shares $27.78 million -4.4%16.4%15.2 $8.60 11/15/20243,380,000 shares $32.21 million -1.7%17.2%20 $9.53 10/31/20243,440,000 shares $38.68 million +0.3%17.5%22 $11.25 10/15/20243,430,000 shares $40.03 million +14.7%17.4%20.7 $11.67 9/30/20242,990,000 shares $30.98 million +2.4%15.2%16.5 $10.36 9/15/20242,920,000 shares $36.30 million +0.3%14.8%16.9 $12.43 8/31/20242,910,000 shares $37.48 million -1.7%14.8%16.7 $12.88 8/15/20242,960,000 shares $36.29 million +5.7%15.0%16 $12.26 7/31/20242,800,000 shares $41.33 million -3.8%14.2%15.7 $14.76 7/15/20242,910,000 shares $48.13 million -3.3%14.8%16.6 $16.54 6/30/20243,010,000 shares $39.04 million +9.1%15.3%18.3 $12.97 6/15/20242,760,000 shares $35.44 million No Change14.0%15.3 $12.84 5/31/20242,760,000 shares $34.42 million -1.4%14.0%14.7 $12.47 5/15/20242,800,000 shares $37.35 million +0.7%14.2%14.5 $13.34 4/30/20242,780,000 shares $38.20 million +1.5%14.2%12.5 $13.74 4/15/20242,740,000 shares $44.25 million No Change13.9%12 $16.15 3/31/20242,740,000 shares $47.84 million +13.7%13.9%10.4 $17.46 3/15/20242,410,000 shares $34.25 million +15.3%12.3%9.2 $14.21 2/29/20242,090,000 shares $30.03 million -5.4%10.6%8 $14.37 2/15/20242,210,000 shares $29.30 million +20.1%11.2%8.2 $13.26 1/31/20241,840,000 shares $22.36 million +15.7%9.3%6.5 $12.15 1/15/20241,590,000 shares $17.82 million +2.6%8.1%5.4 $11.21 12/31/20231,550,000 shares $14.59 million -13.9%7.9%5.4 $9.41 12/15/20231,800,000 shares $16.81 million +22.5%9.2%6.4 $9.34 11/30/20231,470,000 shares $13.73 million -2.7%7.5%3.4 $9.34 11/15/20231,510,000 shares $13.21 million +12.7%7.7%3.3 $8.75 10/31/20231,340,000 shares $12.09 million +3.9%6.9%3.1 $9.02 10/15/20231,290,000 shares $12.42 million +8.4%6.6%3 $9.63 9/30/20231,190,000 shares $13.29 million -42.0%6.8%2.9 $11.17 9/15/20232,050,000 shares $26.10 million +22.0%10.5%5.2 $12.73 8/31/20231,680,000 shares $24.95 million +16.7%8.6%6 $14.85 8/15/20231,440,000 shares $22.82 million No Change7.4%6.4 $15.85 7/31/20231,440,000 shares $27.32 million +5.9%7.4%6 $18.97 7/15/20231,360,000 shares $26.14 million +14.3%7.0%5.9 $19.22 6/30/20231,190,000 shares $25.47 million +47.3%6.2%5.3 $21.40 6/15/2023808,100 shares $19.54 million +2.3%4.2%3.7 $24.18 5/31/2023789,600 shares $18.54 million +18.2%4.1%3.9 $23.48 5/15/2023667,800 shares $17.28 million -6.4%3.5%3.4 $25.87 4/30/2023713,500 shares $25.36 million -2.4%3.7%3.8 $35.55 4/15/2023730,800 shares $26.70 million +4.8%3.8%4.2 $36.53 3/31/2023697,100 shares $28.19 million -22.6%3.6%3.9 $40.44 3/15/2023900,100 shares $40.06 million +20.0%4.7%5.3 $44.51 2/28/2023750,300 shares $36.39 million -8.4%3.9%4.8 $48.50 2/15/2023819,500 shares $41.12 million -3.8%4.3%5.1 $50.18 1/31/2023851,400 shares $45.45 million +0.4%4.4%5.5 $53.38 1/15/2023847,700 shares $43.62 million -1.6%4.4%5 $51.46 12/30/2022861,500 shares $40.08 million -6.0%4.5%5 $46.52 12/15/2022916,400 shares $40.17 million -11.9%4.8%5.1 $43.84 11/30/20221,040,000 shares $45.54 million +4.2%5.4%5.4 $43.79 11/15/2022998,400 shares $47.14 million -4.0%5.2%4.9 $47.22 10/31/20221,040,000 shares $46.91 million -17.5%5.4%5.1 $45.11 10/15/20221,260,000 shares $59.16 million -2.3%6.5%6 $46.95 9/30/20221,290,000 shares $66.91 million -5.2%6.7%6.4 $51.87 9/15/20221,360,000 shares $78.77 million -8.1%7.0%6.1 $57.92 8/31/20221,480,000 shares $90.10 million -3.3%7.7%6.1 $60.88 8/15/20221,530,000 shares $107.80 million -8.9%7.9%6.1 $70.46 7/31/20221,680,000 shares $92.65 million +3.1%8.7%5.8 $55.15 7/15/20221,630,000 shares $83.64 million -1.8%8.4%5.9 $51.31 6/30/20221,660,000 shares $78.47 million +5.7%8.6%5.8 $47.27 6/15/20221,570,000 shares $62.80 million +6.1%10.7%5.8 $40.00 5/31/20221,480,000 shares $59.10 million +10.5%7.7%6.2 $39.93 5/15/20221,340,000 shares $66.84 million +10.7%6.9%5.5 $49.88 4/30/20221,210,000 shares $77.92 million +9.0%6.3%5.6 $64.40 4/15/20221,110,000 shares $82.42 million -5.9%5.8%5.2 $74.25 3/31/20221,180,000 shares $83.99 million +9.3%6.1%5.4 $71.18 3/15/20221,080,000 shares $70.87 million +21.9%5.6%5.1 $65.62 2/28/2022886,300 shares $62.41 million +13.7%4.6%4 $70.42 2/15/2022779,800 shares $48.51 million -16.5%4.1%3.5 $62.21 1/31/2022933,700 shares $55.48 million +28.6%5.2%4.3 $59.42 1/15/2022726,100 shares $43.57 million +4.0%N/A0 $60.00 12/31/2021697,900 shares $52.19 million -2.4%3.9%3.5 $74.78 12/15/2021715,300 shares $52.22 million +5.4%4.0%3.6 $73.00 11/30/2021678,900 shares $59.93 million -0.3%3.8%3.7 $88.28 11/15/2021681,000 shares $61.21 million -36.9%3.8%4 $89.88 10/29/20211,080,000 shares $92.72 million -32.1%6.1%6.7 $85.85 10/15/20211,590,000 shares $113.64 million -9.7%8.9%10.8 $71.47 9/30/20211,760,000 shares $99.99 million -2.8%9.9%11.8 $56.81 9/15/20211,810,000 shares $106.16 million -7.2%10.1%11.7 $58.65 8/31/20211,950,000 shares $111.54 million -8.9%10.9%12 $57.20 8/13/20212,140,000 shares $100.90 million +4.9%12.0%13.8 $47.15 7/30/20212,040,000 shares $86.19 million +9.1%11.4%13.8 $42.25 7/15/20211,870,000 shares $78.73 million +7.5%10.5%13.5 $42.10 6/30/20211,740,000 shares $76.58 million -7.0%9.8%13.4 $44.01 6/15/20211,870,000 shares $89.57 million -1.6%10.5%15.6 $47.90 5/28/20211,900,000 shares $92.45 million -4.0%10.6%16.9 $48.66 5/14/20211,980,000 shares $99.59 million -2.5%11.1%15.3 $50.30 4/30/20212,030,000 shares $104.24 million -5.1%11.4%14.8 $51.35 4/15/20212,140,000 shares $108.39 million -2.7%12.0%14.6 $50.65 3/31/20212,200,000 shares $105.75 million +1.4%12.3%14.4 $48.07 3/15/20212,170,000 shares $113.25 million +0.5%12.2%13.2 $52.19 2/26/20212,160,000 shares $109.25 million +1.4%12.1%13.1 $50.58 2/12/20212,130,000 shares $114.66 million -9.0%12.0%13.4 $53.83 1/29/20212,340,000 shares $107.83 million -1.7%13.2%14.8 $46.08 1/15/20212,380,000 shares $115.05 million -1.2%13.4%14.3 $48.34 12/31/20202,410,000 shares $100.11 million +5.2%13.6%14.3 $41.54 12/15/20202,290,000 shares $97.33 million -3.0%12.9%13.5 $42.50 11/30/20202,360,000 shares $101.24 million -2.9%13.4%13.7 $42.90 11/15/20202,430,000 shares $109.64 million -2.0%13.7%13.9 $45.12 10/30/20202,480,000 shares $108.92 million +15.4%14.0%14.2 $43.92 ENTA Short Interest - Frequently Asked Questions What is Enanta Pharmaceuticals' current short interest? Short interest is the volume of Enanta Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of September 30th, traders have sold 3,350,000 shares of ENTA short. Learn More on Enanta Pharmaceuticals' current short interest. What is a good short interest ratio for Enanta Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ENTA shares currently have a short interest ratio of 6.0. Learn More on Enanta Pharmaceuticals's short interest ratio. Which institutional investors are shorting Enanta Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Enanta Pharmaceuticals: Group One Trading LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Enanta Pharmaceuticals' short interest increasing or decreasing? Enanta Pharmaceuticals saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 3,350,000 shares, an increase of 17.5% from the previous total of 2,850,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Enanta Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Enanta Pharmaceuticals: Precigen, Inc. (30.78%), Xencor, Inc. (13.03%), Oculis Holding AG (0.05%), Oruka Therapeutics, Inc. (8.58%), BGM Group Ltd. (0.32%), Mind Medicine (MindMed) Inc. (13.59%), Valneva SE Sponsored ADR (0.02%), ProKidney Corp. (10.95%), AnaptysBio, Inc. (27.97%), Kura Oncology, Inc. (11.99%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Corporation ($15.71 billion), Robinhood Markets, Inc. ($7.56 billion), Reddit Inc. ($4.55 billion), Coinbase Global, Inc. ($4.53 billion), CoreWeave Inc. ($4.43 billion), Charter Communications, Inc. ($4.07 billion), Seagate Technology Holdings PLC ($3.94 billion), IonQ, Inc. ($3.78 billion), TC Energy Corporation ($3.13 billion), and Live Nation Entertainment, Inc. ($3.12 billion). View all of the most shorted stocks. What does it mean to sell short Enanta Pharmaceuticals stock? Short selling ENTA is an investing strategy that aims to generate trading profit from Enanta Pharmaceuticals as its price is falling. ENTA shares are trading up $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Enanta Pharmaceuticals? A short squeeze for Enanta Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ENTA, which in turn drives the price of the stock up even further. How often is Enanta Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ENTA, twice per month. The most recent reporting period available is September, 30 2025. More Short Interest Resources from MarketBeat Related Companies Precigen Short Interest Data Xencor Short Interest Data Oculis Short Interest Data Oruka Therapeutics Short Interest Data BGM Group Short Interest Data Mind Medicine (MindMed) Short Interest Data Valneva Short Interest Data ProKidney Short Interest Data AnaptysBio Short Interest Data Kura Oncology Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ENTA) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthFed vs. Trump - A War With American Wealth At Stake The Fed's defiance of Trump thickens the plot to contro...American Hartford Gold | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredIt’s Time to Buy “the NVIDIA of Quantum Computing”Yahoo Finance wrote that investing in quantum computing could... "Lead to life-changing returns... and make...Brownstone Research | SponsoredApple's secret partnerThe Tiny Company Apple Can’t Live Without A tiny company holds the key to Apple’s biggest breakthrough sinc...The Oxford Club | SponsoredTrump cannot stop this trainThere are five truths reshaping America’s financial future — and ignoring them could be costly. From an overex...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
